Vertex Pharmaceuticals announced on Mar. 10 that its investigational fusion protein, povetacicept, showed significant improvement in kidney function for patients with IgA nephropathy based on interim late-stage trial results. The company said these findings will support the completion of its application to the Food and Drug Administration in the coming weeks.
The announcement is important as it could lead to a new treatment option for people with IgA nephropathy, a chronic kidney disease. Vertex expects to finish its rolling biologics license application by the end of March, and analysts at BMO Capital Markets estimate that if accepted, FDA approval could come as early as November.
According to data from the Phase 3 RAINIER study released Monday, patients treated with povetacicept experienced a 49.8% reduction in proteinuria at 36 weeks compared to placebo. Vertex described this effect as “statistically significant and clinically meaningful.” The drug also met key secondary endpoints, including a 79.3% decrease in serum galactose-deficient IgA1 levels versus placebo.
Safety data showed that povetacicept was well-tolerated overall, with no serious adverse events reported. Dropout rates were low: 1.5% in the placebo group and 0.8% among those receiving povetacicept. While anti-drug antibodies were detected, Vertex said they did not affect efficacy.
Analysts have responded positively to the results but raised questions about how povetacicept will compete with other treatments such as Otsuka’s Voyxact, Novartis’ Fabhalta, and Travere Therapeutics’ Filspari. Stifel analysts wrote that while the result "should clearly meet the bar for approval," it remains unclear whether it is differentiated from competitors. BMO analysts noted an advantage after discussions with Vertex management: "povetacicept maintained its efficacy across various patient subgroups," which they view as a competitive edge over Voyxact.
Povetacicept works by inhibiting BAFF and APRIL cytokines involved in immune responses underlying IgA nephropathy and other autoimmune diseases. Vertex CEO Reshma Kewalramani told investors last month that the company plans to expand development of povetacicept into generalized myasthenia gravis.
